Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[123I]NAV5001 for Diagnosis of Parkinsonian Syndromes
NCT01950468Phase 3Withdrawn
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Apr 2017
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of altropane in parkinsonian syndromes, sponsored by Navidea Biopharmaceuticals, Inc.. Planned start Apr 2017; status: withdrawn.
02
Drugs
altropane
03
Conditions
parkinsonian syndromes
Beyond the preview
Go deeper on NCT01950468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01950468.